Compare ORIC & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIC | CRMD |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.3M | 590.7M |
| IPO Year | 2020 | 2009 |
| Metric | ORIC | CRMD |
|---|---|---|
| Price | $14.20 | $8.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $19.73 | $14.83 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.67 | ★ 780.00 |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.43 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $7.23 | $6.13 |
| 52 Week High | $14.93 | $14.96 |
| Indicator | ORIC | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.17 | 54.27 |
| Support Level | $10.45 | $8.09 |
| Resistance Level | $14.14 | $8.93 |
| Average True Range (ATR) | 0.84 | 0.41 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 83.29 | 56.38 |
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.